News

Public · Published

Herbalife Shifts to Broader Health Focus Amid Weight-Loss-Drug Surge — Interview

Herbalife is broadening its focus from weight loss to wider nutritional health as GLP-1 weight-loss drugs surge. Interim CEO John DeSimone said the company is emphasizing protein products, in-person nutrition clubs and sports lines; protein-based products account for 30% of sales. Third-quarter sales rose 6% to $1.35 billion, above analysts' $1.31 billion expectation.

Published:

Updated:

What happened

Herbalife is broadening its focus from weight loss to wider nutritional health as GLP-1 weight-loss drugs surge. Interim CEO John DeSimone said the company is emphasizing protein products, in-person nutrition clubs and sports lines; protein-based products account for 30% of sales. Third-quarter sales rose 6% to $1.35 billion, above analysts’ $1.31 billion expectation.

Confirmed

Global impact / market context

The strategy aims to keep Herbalife’s products relevant as weight-loss drugs reshape consumer choices, by highlighting uses beyond weight loss. Protein already makes up 30% of sales, so sustained demand for these products could support revenue; nutrition clubs and sports lines offer additional routes to attract customers.

Analyst inference

The article presents a mixed backdrop: GLP-1 drugs are driving a surge that challenges Herbalife’s weight-loss positioning, while protein demand and third-quarter sales provide support. Sales exceeded the cited analyst expectation, but the article gives no outlook or evidence that this growth will continue.

Analyst inference

What to watch

  1. Watch whether Herbalife continues to report growth in protein products, which account for 30% of sales, and whether broader nutrition messaging helps sustain that demand. Analyst inference
  2. Track sales at in-person nutrition clubs and the contribution of sports lines, which management identified as growth drivers but did not quantify in the article. Analyst inference
  3. Look for further detail from management on how GLP-1 drug use is changing customer demand and whether the shift in product positioning supports revenue. Analyst inference

Evidence

  • Original source link unavailable